Inflammatory mediators, including prostaglandins, cytokines, and chemokines, are strongly implicated in the mechanism of human labor, though their precise roles remain unknown. Here we demonstrate that interleukin 1 beta (IL-1beta) significantly increased the expression and release of interleukin-8 (CXCL8), monocyte chemotactic protein-1 (CCL2), and granulocyte macrophage colony-stimulating factor (CSF2) by primary human myometrial cells. However, this effect was repressed by prostaglandin E 2 (PGE 2 ). As PGE 2 can activate four distinct PGE 2 receptors (EP 1 , EP 2 , EP 3 , and EP 4 ) to elicit various responses, we sought to define the EP receptor(s) responsible for this repression. Using selective EP receptor agonists and a selective EP 4 antagonist, we show that PGE 2 mediates the repression of IL1beta-induced release of CXCL8, CCL2, and CSF2 via activation of the EP 2 and EP 4 receptors. The use of siRNA gene-specific knockdown further confirmed a role for both receptors. Real-time RT-PCR demonstrated that EP 2 was the most highly expressed of all four EP receptors at the mRNA level in human myometrial cells, and immunocytochemistry showed that EP 2 protein is abundantly present throughout the cells. Interestingly, PGE 2 does not appear to reduce mRNA expression of CXCL8, CCL2, and CSF2. Our results demonstrate that PGE 2 can elicit antiinflammatory responses via activation of the EP 2 and EP 4 receptors in lower segment term pregnant human myometrial cells. Further elucidation of the EP receptor-mediated signaling pathways in the pregnant human uterus may be beneficial for optimizing the maintenance of pregnancy, induction of labor or indeed treatment of preterm labor.
INTRODUCTION
There is a growing body of evidence demonstrating that human labor is an inflammatory process [1, 2] . For example, the onset of labor is associated with increased leukocyte infiltration into gestational tissues [3] [4] [5] and increased expression and release of numerous proinflammatory cytokines and chemokines, including interleukin 1b (IL-1b), interleukin-8 (CXCL8), monocyte chemotactic protein-1 (CCL2), and granulocyte macrophage colony-stimulating factor (CSF2) [6] [7] [8] [9] . These cytokines and chemokines promote the recruitment and maturation of leukocytes in inflamed tissue, further driving the inflammatory process [10] .
Prostaglandins are also strongly implicated in the process of human labor [11] , demonstrated by increased levels of prostaglandin E 2 (PGE 2 ) in fetal membranes, amniotic fluid, and myometrium with labor onset [12] [13] [14] . The biosynthesis of prostaglandins is a multistep process that results in the production of five distinct classes of prostaglandins generated by the action of phospholipase, cyclooxygenase (COX), and specific prostaglandin synthase enzymes [15] . Expression of COX-2 but not COX-1 increases in human myometrium with labor onset at term [16] . In the case of PGE 2 , synthesis can occur via three distinct PGE 2 synthase (PGES) enzymes: cytosolic PGES (cPGES), microsomal PGES-1 (mPGES-1), and microsomal PGES-2 (mPGES-2). All PGES enzymes have been identified in the pregnant human uterus. Both mPGES-1 and mPGES-2 are up-regulated in human myometrium with the onset of labor at term, leading to an increased capacity for PGE 2 synthesis [17] . The biological actions of PGE 2 are mediated by one of four distinct receptor subtypes, designated EP 1 , EP 2 , EP 3 , and EP 4 [18] , all of which are present in the pregnant human uterus [19, 20] . Thus, the distribution and relative expression of the four EP receptors will determine the final response produced by PGE 2 . Current clinical interventions target the prostaglandin pathway; PGE 2 (dinoprostone) is used to induce labor at term, while prostaglandin synthesis inhibitors are employed to delay preterm labor [21, 22] . However, these interventions are not always successful and can be associated with undesirable fetal side effects. The EP receptors may represent a good target for clinical management of preterm and postterm deliveries due to increased specificity and consequently the potential to minimize side effects.
We have reported previously that IL-1b-induced the expression and release of CXCL8 and CSF2 in human myometrial cells in a manner that required de novo transcription and translation. Moreover, pretreatment of these cells with PGE 2 (1 lM) repressed this effect [23] . These results are somewhat surprising given that PGE 2 has been historically viewed as a proinflammatory mediator and considered to be ''prolabor.'' However, there is now increasing evidence that prostaglandins are also involved in the resolution of inflammation and can in fact have anti-inflammatory effects [24, 25] .
Therefore, we hypothesize that during pregnancy PGE 2 may be involved in maintaining uterine quiescence by promoting an anti-inflammatory state. The objective of the current study was to determine the EP receptor subtype(s) responsible for the PGE 2 -mediated repression of IL-1b-induced CXCL8, CCL2, and CSF2 output from primary cultured human myometrial cells isolated from term pregnancies prior to the onset of labor using pharmacological and molecular approaches.
MATERIALS AND METHODS

Tissue Collection
Myometrial biopsies were collected from the lower uterine segment of pregnant women undergoing elective Cesarean section (CS) at term prior to the onset of labor. The gestational age range was 38 wk þ 1 day to 39 wk þ 2 days, and there were no clinical signs of labor. Indications for CS included breech presentation, previous CS, or maternal request. Institutional ethical committee approval was obtained, and all patients completed written informed consent (Ethics ID: E-20272 and E-23617 Conjoint Health Research Ethics Board, Office of Medical Bioethics, University of Calgary).
Isolation and Culture of Human Myometrial Cells
Human myometrial cells were isolated from myometrial biopsies as described previously [17] . Briefly, myometrial biopsies were dissected into small pieces, washed in Hanks Balanced Salt Solution (HBSS; Invitrogen), and incubated in Dubelco modified Eagle medium (DMEM; Invitrogen) containing collagenase XI and collagenase IA (Sigma-Aldrich) for 30 min at 378C. Cells were dissociated by tituration through a sterile pipette, and further digestion was stopped by adding DMEM containing 10% fetal bovine serum (FBS; Invitrogen). Cells were then passed through a 70-lm sieve, centrifuged for 5 min. at 800 rpm, resuspended in DMEM containing 10% FBS, L-glutamine (Invitrogen) and antibiotic-antimycotic fungizone (Invitrogen), plated in 25-cm 2 culture flasks, and incubated at 378C in a humidified atmosphere of 95% air/5% CO 2 . Culture medium was changed every 2 days until cells reached ;90% confluence. Flasks were subcultured regularly, and cells were seeded in 12-well plates, 24-well plates, and glass culture slides for experiments. These human myometrial cells represent a homogeneous population that stains positively for smooth muscle markers (a actin, calponin, caldesmon). Prior to drug treatments, cells were serum deprived overnight with DMEM containing 0.5% FBS. Drug dilutions were made in fresh serum-deprived medium. Cells were treated with EP receptor agonists and antagonists as indicated in the text (see Table 1 for details) with and without IL-1b (1 ng/ml; Research & Development Systems) and incubated for 18 h. All experiments were performed in the presence of indomethacin (10 lM) to inhibit the production of endogenous prostaglandins. Culture supernatants were harvested and cell culture plates were stored at À808C prior to RNA or protein isolation. A total of nine different patients were used for biopsy collection and cell isolation. Selection of patients was random with at least n ¼ 3 patients used for each experiment.
siRNA Mediated Gene Knockdown
Primary human myometrial cells were transfected with small interfering RNA molecules designed to target PTGER2 and PTGER4 and a scrambled control siRNA (Table 2 ; Qiagen Inc.). At ;70% confluence, cells were transfected and incubated for 24 h with RNAiMAX Lipofectamine (Invitrogen) and 1 lM siRNA in DMEM containing no FBS. The culture medium was then switched to DMEM containing 0.5% FBS, and human myometrial cells were subsequently treated with PGE 2 and IL-1b. 
Measurement of CXCL8, CCL2, and CSF2
CXCL8, CCL2, and CSF2 released into culture supernatant was quantified by a sandwich ELISA (Human DuoSet; Research & Development Systems) according to the manufacturer's instructions. Optical density was measured at 450 nm using a DTX880 Multimode Detector (Beckman Coulter Canada, Inc.).
RNA Isolation and Real-Time RT-PCR
Total RNA was isolated from human myometrial cells using Qiagen RNeasy kits (Qiagen), and 500 ng were used for reverse transcription and synthesis of complementary DNA (cDNA) with qScript cDNA SuperMix (Quanta BioSciences). The resultant cDNA was used as a template to perform RT-PCR using gene-specific primers as appropriate (Table 3) . A negative RT reaction was also performed in which the RT enzyme was absent. Real-time analysis was performed using an Applied Biosystems 7900HT machine in 96-well Applied Biosystems MicroAmp Fast Optical Plates with SYBR Green qPCR SuperMix (Quanta BioSciences). All protocols were performed according to the manufacturer's instructions. Following amplification, melt curve analysis was performed to verify that nonspecific amplification products were not present. Gene expression was normalized to the housekeeping gene b2-microglobulin (b2M).
Western Blot Analysis
Protein was isolated from human myometrial cells using the Qiagen Mammalian Qproteome protein purification kit (Qiagen) according to the manufacturer's instructions. Protein samples (10 lg) were separated on precast 4-12% Bis-Tris gels (Invitrogen) and transferred to Hybond-ECL membranes (GE Healthcare Bio-Sciences). Membranes were blocked in 5% blocking solution (1 g powdered skim milk, 20 ml Tris-buffered saline-Tween [TBS-T]) for 1 h at room temperature and then incubated with primary antibody (Table 4) overnight at 48C. Membranes were washed in TBS-T followed by incubation with goat anti-rabbit secondary antibody for 1 h at room temperature and then developed with ECL solution. The immunoblot image was acquired with Fujifilm LAS-4000 programmed for chemiluminescent detection. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a protein loading control.
Immunocytochemistry
Human myometrial cells were plated onto clear glass culture slides (Fisher Scientific), grown to confluence, and then rinsed in PBS. Cells were fixed in 4% paraformaldehyde for 20 min at 378C and permeabilized in 0.1% Triton-X for 15 min at room temperature. Cells were then treated using a DAKO kit (DAKO Canada, Inc.) according to the manufacturer's instructions. Briefly, cells were incubated for 10 min in 1.5% blocking serum in PBS at room temperature prior to incubation with primary antibody (Table 4) . Cells were washed in PBS and incubated with biotinylated goat anti-rabbit and anti-mouse secondary antibody followed by peroxidase substrate. Finally, cells were counterstained in Harris hematoxylin and mounted with DAKO Faramount Aqueous Mounting Medium. Images were obtained using a Zeiss Axio Scope.A1 connected to an Axiocam ICc 3 camera and AxioVision 4.8.2 software (Carl Zeiss Canada Ltd).
Statistical Analysis
Data are presented as the mean 6 SEM. Comparison of two means was made using a two-tailed Student t test. Multiple comparisons were made using one-way analysis of variance (ANOVA) with Bartlett test for equal variances. Nonlinear regression was used to determine logEC 50 values. All statistics were performed with GraphPad PRISM Software (GraphPad Software Inc.), and P , 0.05 was considered statistically significant.
RESULTS
PGE 2 Represses IL-1b-Induced Output of CXCL8, CCL2, and CSF2 from Human Myometrial Cells
Treatment of human myometrial cells with IL-1b (1 ng/ml) resulted in a significant increase in CXCL8, CCL2, and CSF2 output compared to nonstimulated controls. Administration of PGE 2 (300 pM, 10 lM) prior to IL-1b treatment resulted in a concentration-dependent repression of CXCL8, CCL2, and CSF2 output (logEC 50 values ¼ À8.02, À7.79, and À7.82, respectively; Fig. 1 ). At the maximally effective concentration of PGE 2 (10 lM), inflammatory mediator output was repressed by over 60%. PGE 2 in the absence of IL-1b had no effect on inflammatory mediator output (Table 5) . To determine the EP receptor(s) responsible for mediating the repressive effect of PGE 2 on inflammatory mediator output, selective agonists for the EP 1 , EP 2 , EP 3 , and EP 4 receptors were used. Butaprost and ONO-AE1-259, selective EP 2 receptor agonists, and ONO-AE1-329, a selective EP 4 receptor agonist, caused a significant repression of CXCL8, CCL2, and CSF2 output (Fig. 2 and Supplemental Figure S1 ; all supplemental data are available online at www.biolreprod. org). In contrast, sulprostone, an EP 1 /EP 3 agonist; ONO-DI-004, a selective EP 1 receptor agonist; and ONO-AE-248, a selective EP 3 receptor agonist, did not alter CXCL8, CCL2, and CSF2 output (Fig. 2 and Supplemental Figure S1 ). None of the EP receptor agonists had any effect on inflammatory mediator release in the absence of IL-1b (Table 5 ). To determine if the combined activation of the EP 2 and EP 4 receptors would enhance the repressive effect, cells were treated with ONO-AE1-259 and ONO-AE1-329 simultaneously. Maximally effective concentrations of ONO-AE1-259 and ONO-AE1-329 in combination did not repress release of the inflammatory mediators above the effect produced by either compound alone (Supplemental Figure S2) . 4 receptor agonist (ONO-AE1-329). After 15 min, IL-1b (1 ng/ml) was added to the cells, which were incubated for 18 h. CXCL8, CCL2, and CSF2 were quantified by ELISA. Data represent the mean 6 SEM for n ¼ 3 patients, and experiments were performed in duplicate. Analysis was performed by Student t test. *P , 0.05, **P , 0.01, ***P , 0.001.
MOSHER ET AL.
Pretreatment of human myometrial cells with the EP 4 receptor antagonist L-161,982 blocked the ability of PGE 2 to repress inflammatory mediator output (Fig. 3) . Furthermore, transfection of human myometrial cells with siRNA molecules targeting PTGER2 or PTGER4 significantly attenuated the ability of PGE 2 to repress IL-1b-induced CXCL8, CCL2, and CSF2 output. The scrambled control siRNA had no effect on PGE 2 -mediated repression of inflammatory mediator release (Fig. 4) . Knockdown of PTGER2 and PTGER4 was confirmed at both the mRNA level by real-time RT-PCR and the protein level by Western blotting (Fig. 4D) .
EP 2 Receptor Expression Is Greater Than EP 1 , EP 3 , and EP 4 Receptor Expression in Human Myometrial Cells
Expression of all four PTGER receptor subtypes in human myometrial cells was confirmed by real-time RT-PCR. PTGER2 was the most highly expressed receptor subtype in human myometrial cells isolated at term prior to labor onset (PTGER2 . PTGER3 . PTGER4 . PTGER1; Fig. 5 ). The efficiency of the PCR reaction was determined by performing PCR using a serial dilution of purified product as a template. The slope of C T values for all four PTGER receptors fell within the range of 3.2-3.5. In addition, EP receptor protein expression in human myometrial cells was confirmed by immunocytochemistry where staining of the EP 2 receptor was the most prominent of the four EP receptors. Smooth muscle aactin was used as a positive control (Fig. 6) .
CXCL8, CCL2, and CSF2 Are Not Repressed by PGE 2 at the mRNA Level
Real-time RT-PCR data demonstrated that CXCL8, CCL2, and CSF2 mRNA expression was significantly up-regulated in response to IL-1b (Fig. 7) , which was similar to the results obtained at the protein level (Fig. 1) . However, PGE 2 did not inhibit the IL-1b-induced mRNA expression of CXCL8, CCL2, and CSF2 (Fig. 7) .
DISCUSSION
In this study, we demonstrate that PGE 2 repressed IL-1b-induced CXCL8, CCL2, and CSF2 output from human myometrial cells in a concentration-dependent manner. PGE 2 mediated this repression by acting through either of the EP 2 and EP 4 receptors; neither the EP 1 receptor nor the EP 3 receptor was involved. A role for the EP 2 and EP 4 receptors was established by the use of selective EP receptor agonists, a selective EP 4 receptor antagonist, and selective EP 2 or EP 4 RNA interference. Since increased expression and release of CXCL8, CCL2, and CSF2 typically causes an increase in tissue inflammation, these data suggest that PGE 2 can behave in an anti-inflammatory manner in these cells and that PGE 2 is capable of producing effects that may be considered ''propregnancy'' rather than ''prolabor.''. As such, in order to optimize therapeutic approaches for preterm labor and labor induction, it is important to distinguish the EP receptors and signaling pathways that are necessary for the maintenance of pregnancy from those that are involved in the initiation of labor.
The role of PGE 2 as an anti-inflammatory mediator within the pregnant uterus may seem counterintuitive given that labor is considered an inflammatory process, that PGE 2 synthesis is increased in myometrial tissues following labor [14, 17] , and that PGE 2 is used to induce labor [22] . There may be a shift in EP receptor expression with the onset of labor, in effect switching the actions of PGE 2 toward a contractile, prolabor role. Additionally, increased PGE 2 levels could be important for the resolution of inflammation following labor and delivery. An important aspect of the current work is that the myometrial cells were isolated from tissue that was obtained from the lower segment of the uterus in term nonlaboring women. Earlier studies in rats have found that EP 2 receptor mRNA expression increases throughout gestation and then decreases at term [26] . Human myometrial cells were incubated in low serum medium containing indomethacin (10 lM) for 30 min followed by a second 30-min incubation with the EP 4 receptor antagonist L-161,982 at concentrations of 10 nM and 1 lM. Cells were then treated with PGE 2 and subsequently IL-1b. CXCL8, CCL2, and CSF2 were quantified by ELISA. Data represent the mean 6 SEM for n ¼ 3 patients, and experiments were performed in duplicate. Analysis was performed by Student t test. *P , 0.05, **P , 0.01; ns, not significant.
PGE2 REPRESSES INFLAMMATORY OUTPUT VIA EP AND EP 4
In humans, EP 3 receptor expression is decreased in pregnant myometrium compared to nonpregnant myometrium [27] . In terms of EP receptor expression, the concept of regionalization (upper vs. lower segment) of the pregnant uterus has previously been suggested in both baboon and human [20, 28, 29] . Changes in the relative expression of the EP receptors in both the upper and the lower segments of the uterus could give rise to distinct functional responses both throughout pregnancy and during labor. The upper segment may become more contractile during labor while the lower segment relaxes to allow descent of the fetus. Our current data show that EP 2 is the most abundant EP receptor in lower segment human myometrial cells at term prior to the onset of labor. Data in myometrial tissue samples demonstrated that EP 3 mRNA expression was greater in the upper segment compared to the lower segment, while EP 2 mRNA expression was greater in the lower segment compared to the upper segment [20] . It will be interesting to define if there are also spatial changes in the downstream EP signaling mediators in human myometrium with labor at term or preterm.
Labor is increasingly viewed as a proinflammatory event because of the involvement of inflammatory mediators, FIG. 4. PTGER2 and PTGER4 siRNA abolish the ability of PGE 2 to repress IL-1b-induced CXCL8 (A), CCL2 (B), and CSF2 (C) output. Human myometrial cells were transfected with siRNA targeting PTGER2, PTGER4, and a scrambled siRNA control and incubated for 24 h in serum-free medium. Cells were then treated with PGE 2 and subsequently IL-1b. CXCL8, CCL2, and CSF2 were quantified by ELISA. D) Knockdown of PTGER2 and PTGER4 expression. PTGER2 and PTGER4 mRNA expression was quantified using real-time RT-PCR and normalized to b2-microglobulin (b2M) expression. EP2 and EP4 protein expression was measured by Western blotting with GAPDH serving as a loading control. Data represent the mean 6 SEM for n ¼ 3 patients, and experiments were performed in duplicate. Analysis was performed by Student t test. *P , 0.05, **P , 0.01, ***P , 0.001; ns, not significant. including prostaglandins, cytokines, chemokines, and leukocytes [30, 31] . Several studies have implicated an up-regulation in CXCL8 expression as an important factor in the labor process. CXCL8 mRNA and protein expression is significantly higher in myometrium of laboring women at term compared to nonlaboring women [32] . Moreover, CXCL8 mRNA expression has been shown to be increased during cervical ripening, with greatest expression observed postpartum [33] . One study showed that women with high levels of CXCL8 in cervical mucus are more likely to deliver preterm [34] . CXCL8 is involved in recruiting leukocytes, which is important for the protection of the mother during labor, when the threat of infection is high. PGE 2 may act to prevent this from happening during pregnancy and, as such, repress CXCL8 in term nonlaboring women.
We previously demonstrated that PGE 2 represses IL-1b-induced CXCL8 and CSF2 output from cultured human myometrial cells [23] . Similarly, PGE 2 has been shown to repress lipopolysaccharide-induced CXCL8, CCL2, and TNFa output from human macrophages by activation of the EP 2 and/or EP 4 receptor [35, 36] . Furthermore, PGE 2 has also been reported to inhibit IL-1b-induced CCL2 output from human and rabbit synovial fibroblasts by activation of the EP 2 and EP 4 receptors [37] and IL-1b-induced CSF2 output from human airway smooth muscle cells by activation of the EP 2 receptor [25] . Our results now implicate EP 2 and EP 4 as the receptors responsible for the PGE 2 -mediated repression of IL-1b-induced CXCL8, CCL2, and CSF2 output from human myometrial cells. In contrast to the above findings, PGE 2 , acting via the EP 4 receptor, can actually augment rather than repress CXCL8 output from colonic epithelial cells [38] , suggesting that the ability of PGE 2 to modulate inflammatory mediator output may be tissue/cell dependent. This may also imply that the role of PGE 2 in modulating inflammatory mediator release in human myometrium could differ before and after the onset of labor and at different stages of gestation.
Following activation by PGE 2 , the EP 2 and EP 4 receptors couple to the G protein Ga s to promote an increase in adenylyl 4 cyclase activity and generation of the second messenger signaling molecule cAMP [39, 40] . Subsequently, cAMP stimulates downstream effectors such as protein kinase A (PKA) and/or exchange proteins activated by cAMP (Epac), which ultimately lead to smooth muscle relaxation and/or antiinflammatory outcomes [18] . Conversely, the EP 1 and EP 3 receptors couple to Ga q to increase phospholipase C activity and production of diacylglycerol and inositol 1,4,5-trisphosphate (IP 3 ). IP 3 increases intracellular Ca 2þ concentration, resulting in smooth muscle contraction. Additionally, EP 3 can couple Ga i to inhibit adenylyl cyclase activity, leading to decreased cAMP generation [41] . Finally, adding to the complexity, EP 3 is regulated by alternative mRNA splicing and may also couple to Ga s to stimulate adenylyl cyclase [42] . Thus, activation of distinct EP receptors may elicit either antiinflammatory/relaxatory or contractile responses, depending on which of the downstream signaling pathways are stimulated [35] [36] [37] [38] [39] [40] [41] [42] [43] .
PGE2 REPRESSES INFLAMMATORY OUTPUT VIA EP AND EP
Previous data from our group have shown that the cAMP analog 8-Br-cAMP and the phosphodiesterase-4 inhibitor rolipram can repress inflammatory mediator release from human myometrial cells [23] . We now demonstrate that the adenylyl cyclase activator forskolin also represses inflammatory mediator output (Supplemental Figure S3) . Together, these data suggest that the cAMP pathway is involved in the PGE 2 -mediated repression of inflammatory mediator release. Experiments to determine the precise role of the cAMP pathway in human myometrial cells are ongoing.
Interestingly, we show that the PGE 2 -mediated repression of CXCL8, CCL2, and CSF2 occurs at the protein level but not the mRNA level (Figs. 1 and 7 ). This suggests that the mechanism through which PGE 2 represses CXCL8, CCL2, and CSF2 release is not likely to inhibit mRNA transcription. It is possible that downstream effectors of the cAMP pathway, PKA and Epac, target CXCL8, CCL2, and CSF2 protein for degradation, block the translation of the mRNA transcripts, or perhaps block the release or secretion of these mediators from the cell.
The mechanism by which IL-1b up-regulates CXCL8, CCL2, and CSF2 mRNA expression was not investigated in this study, but other groups have demonstrated a potential role for the transcription factor nuclear factor kappa B (NF-jB) [9, 44] . Furthermore, the mechanical stretch exerted by the growing fetus may also play a role in stimulating the expression of inflammatory mediators. In a model of unilaterally pregnant rats, CCL2 expression was increased only in the gravid horn [45] . It remains to be determined whether inflammation is a cause or a consequence of labor. Interestingly, a recent study demonstrates that macrophages infiltrate the decidua prior to labor onset in rat and human [46] . However, decidual chemokines and cytokines were not investigated in the current study.
Preterm births continue to account for a significant proportion of neonatal morbidity and mortality [47] . There are no effective diagnostic indicators for preterm labor. Current treatments include prostaglandin synthesis inhibitors, oxytocin receptor antagonists, b 2 -adrenoceptor agonists, and calcium channel blockers, which attempt to arrest myometrial contractions [48] . However, these treatments have not demonstrated a significant improvement in outcome for the mother or baby. Targeting myometrial contractions may be too late an event in the labor process, and it is possible that treatments also need to target the precipitating inflammatory response. A better understanding of chemokines and cytokines and their interaction with prostaglandins during labor and the postlabor resolution of inflammation in the human uterus is an important step toward better clinical management of labor both at term and preterm. Our results indicate that the anti-inflammatory nature of EP 2 and EP 4 receptor activation in the pregnant FIG. 7. PGE 2 -mediated repression of inflammatory output does not occur at the mRNA level. Total RNA was isolated from human myometrial cells used in experiments in Figure 1 , and cDNA synthesis was performed. Using real-time RT-PCR, CXCL8 (A), CCL2 (B), and CSF2 (C) mRNA expression was quantified and normalized to b2-microglobulin (b2M) expression. Data represent the mean 6 SEM for n ¼ 5 patients, and experiments were performed in duplicate. Analysis was performed by Student t test. *P , 0.05, ***P , 0.001. myometrium may prove beneficial for the maintenance of pregnancy and consequently the management of preterm labor. It is interesting to speculate that, in fact, the EP 4 receptor may be an equally attractive candidate despite the significantly lower expression than the EP 2 receptor since the contribution of the EP 4 receptor to repression of inflammatory output is comparable to that of the EP 2 receptor. Indeed, activation of the EP 4 receptor has demonstrated therapeutic anti-inflammatory activity in conditions such as atherosclerosis and abdominal aortic aneurysms [49] .
In conclusion, we have shown in the present study that PGE 2 significantly repressed IL-1b-induced CXCL8, CCL2, and CSF2 release from human myometrial cells through activation of the EP 2 and EP 4 receptors. These data support the hypothesis that PGE 2 may promote uterine quiescence by repressing inflammatory mediators in term nonlaboring lower segment myometrial cells. Future work will investigate whether this PGE 2 -mediated anti-inflammatory effect also occurs in upper segment myometrial cells and in cells obtained from laboring patients.
